Skip to main content

In gene therapy of adenosine deaminase (ADA) deficiency, the patient requires a periodic infusion of genetically engineered lymphocytes because:

NEET UG 2022 — Zoology Biotechnology and Its Applications

2022mcqmedium

In gene therapy of adenosine deaminase (ADA) deficiency, the patient requires a periodic infusion of genetically engineered lymphocytes because:

Official previous-year question

Held on 30 Apr 2022 · Verified 9 Jul 2026.

Options

  1. A

    Gene isolated from marrow cells producing ADA is introduced into cells at embryonic stages

  2. B

    Lymphocytes from patient's blood are grown in culture, outside the body.

  3. C

    Genetically engineered lymphocytes are not immortal cells.

  4. D

    Retroviral vector is introduced into these lymphocytes.

Did you get this right?

Sign in to track your attempts and accuracy.

Your note

Sign in to keep a private note on this question. Nothing you write is ever public.

NEET UG Biotechnology and Its Applications in other years

More NEET UG Biotechnology and Its Applications questions

Other Zoology topics for NEET UG

Keep practicing Biotechnology and Its Applications

Work through every NEET UG Biotechnology and Its Applications PYQ, year by year.

Browse all Zoology topics